J&J wins China nod for oral psoriasis pill (JNJ:NYSE)
· seekingalpha.com
Johnson & Johnson (JNJ) has won China approval for Icotyde, a once-daily pill developed with Protagonist Therapeutics (PTGX) for plaque psoriasis. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...